Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | LYPD3 |
| Gene Name: | LYPD3 |
| Protein Full Name: | Ly6/PLAUR domain-containing protein 3 |
| Alias: | GPI-anchored metastasis-associated protein C4.4A homologue |
| Mass (Da): | 35953 |
| Number AA: | 346 |
| UniProt ID: | O95274 |
| Locus ID: | 27076 |
| COSMIC ID: | LYPD3 |
| Gene location on chromosome: | 19q13.31 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.29 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | LYPD3 appears to support cell migration and tumour progression, possibly by playing a role in cell-matrix interactions. Galectin-3, a carbohydrate-binding protein involved in cell migration, invasion and metastasis, has been reported as a ligand for LYPD3. LYPD3 may also be a substrate for ADAM10 and ADAM17 which are involved in cell migration and proliferation. High levels of LYPD3 have been associated with poor prognosis in patients with non-small cell lung cancer and esophageal squamous cell carcinoma. |